Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Petrelintide · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1: Petrelintide + Enicepatide Dosing Regimen 1 | EXPERIMENTAL | - |
| Arm 2: Petrelintide + Enicepatide Dosing Regimen 2 | EXPERIMENTAL | - |
| Arm 3: Petrelintide + Enicepatide Dosing Regimen 3 | EXPERIMENTAL | - |
| Arm 4: Petrelintide-matching Placebo + Enicepatide | EXPERIMENTAL | - |
| Arm 5: Petrelintide + Enicepatide-matching Placebo | EXPERIMENTAL | - |
| Arm 6: Petrelintide-matching Placebo + Enicepatide-matching Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Petrelintide | DRUG | Petrelintide will be administered subcutaneously to participants once weekly |
| Enicepatide | COMBINATION_PRODUCT | Enicepatide will be administered subcutaneously to participants once weekly |
| Petrelintide-matching Placebo | DRUG | Matching placebo to Petrelintide will be administered subcutaneously to participants once weekly |
| Enicepatide-matching Placebo | COMBINATION_PRODUCT | Matching placebo to Enicepatide will be administered subcutaneously to participants once weekly |
Key Inclusion Criteria: * Male or female participants with Body Mass Index (BMI) ≥ 30 kg/m² OR BMI ≥ 27 kg/m² to \< 30 kg/m² with at least one weight-related comorbidity * History of at least one self-reported unsuccessful dietary effort to lose body weight Key Exclusion Criteria: * HbA1c ≥ 48 mm...
Petrelintide is an investigational small molecule being developed for the treatment of obesity or overweight. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied in adults aged 18 years and older with these conditions.
Petrelintide is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting a Phase 2 clinical trial to evaluate the drug's safety and efficacy in adults with obesity or overweight.
Petrelintide is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The ongoing Phase 2 trial is designed to assess the drug's dosing and effects in adults with obesity or overweight.
Petrelintide is being studied in a Phase 2 clinical trial registered as NCT07589686. This randomized, double-blind, placebo-controlled study is titled 'A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight' and aims to enroll 486 participants.
Petrelintide is a peptide-based small molecule, classified under the '-tide' target class. It is being investigated for its potential to address obesity or overweight, though the specific molecular target has not been disclosed in available information.
No, Petrelintide is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials. The ongoing study, NCT07589686, is a randomized, double-blind, placebo-controlled trial that has not yet begun recruiting participants.